Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Haloprogin: Applied Antifungal Research Workflows
2026-09-10
Haloprogin supports reproducible profiling across dermatophytes, Candida, and selected Gram-positive bacteria, with workflows spanning MIC/MFC testing and topical infection models. Its solvent, matrix, and formulation behavior make assay design especially important when translating in vitro potency into topical efficacy.
-
rTMS, GABAergic Neurons, and Amyloid Clearance in AD
2026-09-10
This study identifies a cellular pathway linking repetitive transcranial magnetic stimulation to amyloid clearance and cognitive recovery in a 5xFAD Alzheimer’s disease model. Its central finding is that rTMS activates GABAergic neurons, increases Cx3cl1-Cx3cr1 signalling, and promotes microglial phagocytosis while reducing plaque burden and neuroinflammatory features.
-
Cy5 Maleimide for Protein Labeling and Condensate Imaging
2026-09-09
Cy5 maleimide enables site-selective cysteine labeling for far-red protein tracking, microscopy, and biomolecular-condensate assays. Its non-sulfonated format is especially useful when researchers need to test how fluorophore chemistry influences molecular partitioning rather than treating every dye as an inert tag.
-
Ciprofloxacin Hydrochloride: Mechanism and Uses
2026-09-09
Ciprofloxacin hydrochloride is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV. Evidence also supports research into inhalational anthrax treatment, antibiotic-combination antagonism, and immunomodulatory effects, but animal and in vitro findings do not establish new clinical indications.
-
A-1331852: Precision BCL-XL Inhibition
2026-09-08
A-1331852 is a selective BCL-XL inhibitor for mapping apoptotic dependence, validating BCL-XL–BIM complex disruption, and testing senolytic strategies in cancer models. This guide translates published BH3-mimetic findings into practical dose-response, apoptosis, and troubleshooting workflows.
-
hCG, H3K27 Methylation, and CXCL10 in Decidua
2026-09-08
The reference study shows that human chorionic gonadotropin suppresses CXCL10 in human decidual stromal cells by promoting EZH2-dependent H3K27 trimethylation at the CXCL10 promoter. This connects placental endocrine signaling with chromatin control of immune-cell recruitment and provides a mechanistic framework for studying maternal–fetal immune tolerance.
-
Biotin-16-UTP: From RNA Labels to Mechanism
2026-09-07
Biotin-16-UTP connects biotin-labeled RNA synthesis with mechanistic questions in cancer biology. Using the LINC02870–EIF4G1–SNAIL axis in hepatocellular carcinoma as an anchor, this article outlines how translational researchers can use affinity-enabled RNA workflows to validate RNA-protein interactions while managing assay, interpretation, and clinical-translation risks.
-
BAY-826: A Causal Lens on Retinal Signaling
2026-09-07
Retinal neurovascular biology is increasingly understood as a coordinated conversation among angiopoietin signaling, Müller cells, PEDF, and neuronal survival. This thought-leadership article positions BAY-826 as a hypothesis-testing research tool rather than an assumed pathway solution, outlining how translational teams can connect chemical perturbation to target engagement, co-culture phenotypes, and causal rescue experiments.
-
RNASEH1-AS1 as an HCC Biomarker
2026-09-05
The reference study integrates TCGA-based bioinformatics, risk modeling, and cell-based validation to identify RNASEH1-AS1 as a prognostic and potentially oncogenic lncRNA in hepatocellular carcinoma. Its findings connect RNASEH1-AS1 expression with tumor grade, survival, immune-cell infiltration, ribosome-related gene networks, and DKC1-dependent RNA stability, while also defining experimental directions for further mechanistic work.
-
AI-10-49: An Assay-First AML Strategy
2026-09-04
AI-10-49 is a selective CBFβ-SMMHC inhibitor for dissecting fusion-driven acute myeloid leukemia. This assay-first guide connects target engagement, RUNX1 chromatin restoration, and the N-MYC/eIF4G1 survival program to practical experimental decisions.
-
Gramine–MTDH Ferroptosis in Triple-Negative Breast Cancer
2026-09-04
This study identifies gramine as a potential inhibitor of triple-negative breast cancer and defines a CUL3–MTDH regulatory mechanism that promotes ferroptosis. Its combination of chemical screening, target-validation assays, ferroptosis rescue experiments, and tumor models provides a useful framework for studying ubiquitin-regulated cell death in TNBC.
-
Cy5 Goat Anti-Mouse IgG (H+L) Antibody Guide
2026-09-03
The Cy5 Goat Anti-Mouse IgG (H+L) Antibody is a Cy5-conjugated secondary antibody for sensitive mouse IgG detection in IHC, ICC, and flow cytometry. Its affinity-purified polyclonal design supports signal amplification, while defined buffer and storage conditions guide reproducible handling.
-
Beyond Viability: Interpreting Cancer Drug Responses
2026-09-03
Hannah R. Schwartz’s dissertation shows why relative viability and fractional viability should not be treated as interchangeable measures of anticancer activity. Its central contribution is a framework that separates growth inhibition from cell killing, helping researchers design more informative response assays and interpret drug effects across time.
-
Brain-to-Spinal Circuits Control Mechanical Allodynia
2026-09-02
This Cell Reports study identifies a contralateral lPBN–hypothalamus–spinal pathway that regulates both the laterality and persistence of mechanical allodynia in mice. Its combination of circuit mapping, cell-type-specific perturbation, behavioral models, and κ-opioid receptor manipulation provides a framework for studying descending pain control and opioid receptor signaling research.
-
Epinephrine Bitartrate: Adrenergic Research Guide
2026-09-02
Epinephrine Bitartrate is a non-selective adrenergic receptor agonist for controlled studies of α- and β-receptor signaling. This guide separates product-dossier specifications from peer-reviewed receptor-binding evidence and provides practical assay boundaries.